press center press release

Annual Changes to the NASDAQ Biotechnology Index


NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 19, 2016.

The following 21 securities will be added to the Index:

Nasdaq AIMT Aimmune Therapeutics, Inc.
Nasdaq ARLZ Aralez Pharmaceuticals Inc.
Nasdaq AVXS AveXis, Inc.
Nasdaq BGNE BeiGene, Ltd.
Nasdaq BOLD Audentes Therapeutics
Nasdaq CLCD CoLucid Pharmaceuticals
Nasdaq CLSD Clearside Biomedical, Inc.
Nasdaq CYTK Cytokinetics, Incorporated
Nasdaq EDIT Editas Medicine, Inc.
Nasdaq GBT Global Blood Therapeutics
Nasdaq ITCI Intra-Cellular Therapies
Nasdaq LOXO Loxo Oncology, Inc.
Nasdaq MNOV Medicinova Inc
Nasdaq NERV Minerva Neurosciences
Nasdaq NH NantHealth, Inc.
Nasdaq NTLA Intellia Therapeutics, Inc.
Nasdaq NVCR NovoCure Limited
Nasdaq ONVO Organovo Holdings Inc
Nasdaq OPK OPKO Health, Inc.
Nasdaq PRTK Paratek Pharmaceuticals, Inc.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

As a result of the re-ranking, the following 37 securities will be removed from the Index:

Nasdaq ADHD Alcobra Ltd.
Nasdaq ADVM Adverum Biotechnologies, Inc.
Nasdaq AFMD Affimed N.V.
Nasdaq AGTC Applied Genetic Technologies Corporation
Nasdaq ANTH Anthera Pharmaceuticals, Inc.
Nasdaq CARA Cara Therapeutics, Inc.
Nasdaq CASC Cascadian Therapeutics, Inc.
Nasdaq CHMA Chiasma, Inc.
Nasdaq CMRX Chimerix, Inc.
Nasdaq CNCE Concert Pharmaceuticals, Inc.
Nasdaq CXRX Concordia International Corp.
Nasdaq DNAI ProNAi Therapeutics, Inc.
Nasdaq DRNA Dicerna Pharmaceuticals, Inc.
Nasdaq DRRX DURECT Corporation
Nasdaq ECYT Endocyte, Inc.
Nasdaq EGLT Egalet Corporation
Nasdaq FLKS Flex Pharma, Inc.
Nasdaq IMDZ Immune Design Corp.
Nasdaq IMGN ImmunoGen, Inc.
Nasdaq INFI Infinity Pharmaceuticals, Inc.
Nasdaq ITEK Inotek Pharmaceuticals Corporation
Nasdaq KMPH KemPharm, Inc.
Nasdaq LIFE aTyr Pharma, Inc.
Nasdaq MNKD MannKind Corporation
Nasdaq NDRM NeuroDerm Ltd.
Nasdaq NEOS Neos Therapeutics, Inc.
Nasdaq OCUL Ocular Therapeutix, Inc.
Nasdaq OREX Orexigen Therapeutics, Inc.
Nasdaq OSIR Osiris Therapeutics, Inc.
Nasdaq OVAS OvaScience Inc.
Nasdaq QURE uniQure N.V.
Nasdaq RGLS Regulus Therapeutics Inc.
Nasdaq SCLN SciClone Pharmaceuticals, Inc.
Nasdaq TKAI Tokai Pharmaceuticals, Inc.
Nasdaq TTPH Tetraphase Pharmaceuticals, Inc.
Nasdaq VTL Vital Therapies, Inc.
Nasdaq ZFGN Zafgen, Inc.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: or

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.


In This Story


Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more